urological tumour group national perspective data from portfolio odp – cut off 23/10/15 includes...

Urological Tumour Group National Perspective

Data from Portfolio ODP – Cut off 23/10/15 Includes data from Bladder, Prostate, Testis, and Renal CSG Portfolios

Data from Portfolio ODP – Cut off 23/10/15

Network2014/2015 2015/2016

Commercial Non-Commercial Total Rank Commercial Non-

Commercial Total Rank

East Midlands 5 445 450 7 12 149 161 11Eastern 88 1001 1089 2 7 374 381 5Greater Manchester 70 347 417 9 47 111 158 12Kent, Surrey and Sussex 23 450 473 6 22 487 509 1North East and North Cumbria 213 210 423 8 160 164 324 6North Thames 28 804 832 3 26 366 392 4North West Coast 45 284 329 13 23 215 238 8North West London 44 301 345 12 0 127 127 14South London 72 1035 1107 1 28 397 425 3South West Peninsula 57 329 386 11 21 203 224 9Thames Valley and South Midlands 3 294 297 14 3 130 133 13Wessex 44 344 388 10 10 202 212 10West Midlands 14 620 634 5 6 296 302 7West of England 12 274 286 15 7 109 116 15Yorkshire and Humber 66 717 783 4 39 449 488 2

Urological Tumour Group National Perspective

Includes data from Bladder, Prostate, Testis, and Renal CSG Portfolios

Urological Tumour Group Open Commercial Studies


Study EM E GM KS

SNE&NC

NTNWC

NWL

SL SWP

TV&SM

Wes

WM

WoE

Y&H

CANC - 3577 - PRIME - PRostate Imaging for Margin Evaluation 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0CANC - 3742 - REASSURE 7 0 11 19 0 0 1 0 13 0 0 0 0 0 4CANC - 4362 - CICERO: Cystoscopic Imaging Collection and Enhancement pROject 0 0 0 0 123 0 0 0 0 0 0 0 0 0 0NCRN - 2484 / SPARTAN - ARN-509 in non-metastatic castration-resistant prostate ca 1 0 6 6 0 0 9 0 20 0 0 3 1 0 2NCRN - 2835: Patterns of Care and Outcomes of Men with Prostate Cancer 0 0 0 0 8 0 0 0 4 0 0 0 0 0 3NCRN - 3012 Olaparib/placebo + abiraterone in mCRPC following prior treatment with docextaxel 0 0 5 0 0 0 0 0 0 1 0 0 0 0 0NCRN - 3089 Radium-223 in patients with bone predominant metastatic CRPC 0 0 0 0 0 1 3 0 7 0 0 0 0 0 0NCRN - 3312 - MPDL3280A VS Chemotherapy in UROTHELIAL Bladder Cancer 4 1 0 0 1 23 10 0 6 2 3 3 3 2 4NCRN428 BiopSave - Validation of a novel proteomic blood test for prostate ca diagnosis 0 0 0 0 491 0 0 0 0 0 0 0 0 0 0NCRN452 - registry of pts with metastatic castrate-resistant prostate ca 0 0 106 17 0 0 49 0 20 114 0 23 13 0 139NCRN456 - DCVAC / Pca vs Placebo in Prostate Cancer 0 3 3 4 3 1 6 0 0 0 0 0 0 5 0NCRN541 - Abiraterone with Different Steroid Regimens in Prostate Cancer 0 0 0 0 0 0 0 0 11 0 0 0 4 0 0


Urological Tumour Group Open Studies


Study EM E G

MKSS

NE&

NCNT

NWC

NWL

SLSWP

TV&SM

Wes

WM

WoE

Y&H

18F-D4-FCH in MIBC 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0ACTIVE SURVEILLANCE 0 0 0 0 0 0 0 0 582 0 0 0 0 0 0ADIUVO 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0AdUP: AdNRGM; VDEPT + GMCSF in locally recurrent prostate cancer 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0A-PREDICT 0 4 2 6 0 7 1 0 13 6 0 0 0 0 5CALIBER 0 0 2 5 1 0 0 0 0 5 0 3 1 0 0CaNCaP02 - CAmbridge Neoadjuvant CAncer of the Prostate Study 2 0 16 0 0 0 0 0 0 0 0 0 0 0 0 0CANTATA 0 0 0 1 0 0 0 0 0 5 0 0 4 0 1DELINEATE 0 0 0 0 0 0 0 0 154 0 0 0 0 0 0DIRECTS 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0EAGLE study 0 0 0 19 0 0 0 0 0 0 0 0 0 0 80Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) 0 49 0 0 0 0 0 0 0 0 0 0 0 0 0ENZAMET 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0FIESTA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14FORECAST - Focal Recurrent Assessment and Salvage Treatment 0 0 0 0 0 46 0 0 0 0 0 0 0 0 0Genetics of Papillary Kidney Cancer 36 4 3 1 22 36 0 29 15 0 46 9 9 0 17HYBRID 0 12 0 0 0 2 12 0 9 0 0 0 0 0 1Hyperthermia for Intermediate risk bladder cancer (HIVEC-II) 0 2 3 13 12 29 2 0 1 9 0 0 8 0 0IDEAL 0 0 0 0 0 0 0 0 113 0 0 0 0 0 0Immunotherapy for prostate cancer 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0




Study EM E GM KS

SNE&

NCNT

NWC

NWL

SLSWP

TV&SM

Wes

WM

WoE

Y&H

IMPACT 31 33 114 0 45 30 24 57 145 45 39 91 215 17 68Impact of Zoledronic acid and IL2 on gamma delta T cells 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0INDEX 0 0 0 0 0 134 0 24 33 0 25 26 0 25 0JAVA-P 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0LOCATE 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0MARBLE 0 0 0 0 17 0 0 0 0 0 0 0 0 0 0MARS (formerly Microbiota & Radiotherapy (M & RT) Study) 0 0 0 0 0 0 0 0 135 0 0 0 0 0 0MELCAP 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0METformin And Longevity (METAL) 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0MR Elastography assessment of renal tissue biomechanics 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0NEOBLADE 0 0 0 0 0 0 17 0 0 0 0 3 0 0 1PANTERA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 19PART - Partial prostate Ablation versus Radical prosTatectomy 0 0 0 0 0 0 0 0 0 0 11 0 0 0 0PATCH 54 32 65 86 43 2 19 98 8 0 54 0 32 14 282Patient reported outcomes in prostate cancer radiotherapy 31 63 0 17 0 5 40 0 23 0 0 0 16 0 0Pazopanib in patients with renal cancer (PaZ02) 4 9 0 1 1 3 2 0 0 2 0 1 5 13 6PET /MRI preRadiOtherapy for PostProstatectomy 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0POUT 6 5 7 4 17 7 22 7 1 11 0 9 19 7 13ProCAID 0 0 0 0 0 0 0 0 1 0 0 9 0 0 0PROGENY 0 0 0 0 0 48 0 0 0 0 0 0 0 0 0




Study EM E GM KSSNE&NC

NT NWC

NWL SL SW

PTV&SM

Wes

WM

WoE Y&H

PROMIS Prostate MRI Imaging Study (MRC PR11) 0 0 0 37 0 322 0 39 0 36 0 184 0 44 37ProMPT 0 2928 0 0 247 0 0 0 0 0 1073 0 0 0 500PROMPTS 5 79 0 20 10 30 0 0 12 7 0 8 31 2 31ProSpare II 0 0 0 0 0 0 0 0 37 0 0 0 0 0 0RADICALS (MRC PR10) 137 195 196 227 32 176 99 50 280 149 54 124 335 147 299RE-AKT 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0REASURE (Radium-223: Evaluation of Activity and SUrrogate REsponse) 0 2 0 0 0 0 0 0 3 0 0 0 0 0 0SAPROCAN: Saracatnib and docetaxel in met, cast-ref prostate cancer 0 5 10 10 0 4 8 0 10 5 7 14 0 13 12Shed tumour cells in bladder cancer 0 0 22 0 0 0 0 0 0 0 0 0 0 0 16SMART TARGET (Biopsy Study) 0 0 0 0 0 76 0 0 0 0 0 0 0 0 0STAMPEDE 323 286 533 573 281 447 653 41 327 428 242 411 854 224 517STAR Standard vs Modified Drug Therapy in Renal Cancer 22 51 16 8 18 47 37 1 26 10 0 34 7 12 141SURAB 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0Surtime - EORTC 30073 0 0 0 0 0 3 0 0 0 0 0 0 0 2 0The Late CT Study 0 41 0 13 0 0 0 0 157 0 0 0 0 0 0The Leeds Testicular Cancer Study 0 0 0 0 0 143 0 0 0 97 0 46 0 0 397The PACE Study 0 73 0 0 0 0 0 0 157 0 0 0 0 0 0The PHOTO Trial 0 0 0 10 24 2 0 1 0 30 13 3 0 0 5The PROFILE Study 0 0 0 0 0 0 0 0 33 0 0 0 0 0 0The UK Genetics of Testicular Cancer Study 484 475 184 280 627 123 299 444 693 133 198 246 383 830 1238




Study EM E GM KSSNE&NC

NT NWC

NWL SL SW

PTV&SM

Wes

WM

WoE

Y&H

TOPARP 0 0 1 0 0 0 1 0 47 0 1 0 0 0 2TOTEM: Trial of Temsirolimus for Advanced Cancers 0 11 0 0 0 0 0 0 0 0 0 0 0 0 0Tractomap - MRI with DTI tractography to road-map prostatic neurovascular bundles 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0TUXEDO 0 0 0 0 0 0 6 0 0 0 0 0 9 0 0UK Genetic Prostate Cancer Study 651 689 804 771 239 826 396 352 6047 473 643 428 962 503 818Understanding Consequences 0 0 0 0 0 0 0 0 0 0 0 20 0 0 0VinCaP 0 0 4 0 0 2 2 0 2 2 0 0 0 0 0VoxTox - Linking radiation dose at the voxel level with toxicity 0 708 0 0 0 0 0 0 0 0 0 0 0 0 0


Skin Tumour Group SWP Recruitment

Data from Portfolio ODP – Cut off 23/10/15 Includes data from Bladder, Prostate, Testis, and Renal CSG Portfolios

Skin Tumour Group SWP Recruitment


Trust2014/2015 2015/2016

Commercial Non-Commercial Total Commercial Non-

Commercial Total

Northern Devon Healthcare NHS Trust 5 23 28 2 11 13Plymouth Hospitals NHS Trust 21 35 56 6 32 38Royal Cornwall Hospitals NHS Trust 0 75 75 2 28 30Royal Devon and Exeter NHS Foundation Trust 0 94 94 1 86 87Taunton and Somerset NHS Foundation Trust 23 55 78 7 29 36Torbay and South Devon NHS Foundation Trust 8 27 35 3 14 17Yeovil District Hospital NHS Foundation Trust 0 20 20 0 3 3


Acronym UKCRNID Study Type Trust Investigator Name

Recruitment End Date

Planned Target

Recruitment (Edge) RTT

AZD081DC00008 Metastatic Castrate Resistant Prostate Cancer 16081 Commercial PHNT Pascoe, Dr

Sarah 30-Jun-15 2 1 -72

AZD081DC00008 Metastatic Castrate Resistant Prostate Cancer 16081 Commercial SDHCFT Lydon, Dr

Anna 01-Jun-15 4 0 -135

CANC - 4381 PREMISE 18961 Commercial RCHT Wheatley, Dr Duncan 20-Jul-17 10 0 -1

CANC - 4381 PREMISE 18961 Commercial SDHCFT Lydon, Dr Anna 30-Jul-17 10 0 -6

GO29294 AntiPDL1 Bladder Cancer Phase III 18174 Commercial RCHT Wheatley, Dr Duncan 03-Aug-16 2 1 7

GO29294 AntiPDL1 Bladder Cancer Phase III 18174 Commercial RD&E Srinivasan, Dr Rajaguru 15-Jun-18 5 0 -11

Janssen Prostate Study - CANC - 4225 - JNJ56021927+Abiraterone Acetate+Prednisone VS Abiraterone Acetate+Prednisone in mCRPC

18838 Commercial PHNT Natale, Mr Salvatore 20-Dec-18 5 1 10

NCRN 2630 Bayer 16507 Standard dose versus higher and extended dose of Radium 223 in CRPC. 16327 Commercial T&S Graham, Dr

John 16-Jun-16 8 5 -3

NCRN452 13556 Commercial NDHCT Sheehan, Dr Denise 31-Dec-15 12 10 -7

NCRN452 13556 Commercial PHNT Pascoe, Dr Sarah 26-Mar-18 20 40 149

Skin Tumour Group RAG Report - Commercial

Data from EDGE– Cut off 06/10/15 Includes data from Bladder, Prostate, Testis, and Renal CSG Portfolios



Planned Target


Add-Aspirin Trial 18067 Non-Commercial RCHT Wheatley, Dr

Duncan 01-Jul-20 325 0 -6

A-PREDICT 12404 Non-Commercial PHNT Highley, Dr

Martin 01-Sep-14 4 6 -7

CALIBER 17640 Non-Commercial RD&E McGrath, Mr

John 31-Jan-18 7 5 50

CANTATA 13741 Non-Commercial RD&E Sheehan, Dr

Denise 29-Feb-16 4 5 46

CANTATA 13741 Non-Commercial SDHCFT Lydon, Dr

Anna 28-Feb-16 6 0 -73

COMPARe study: COMparing treatment options for ProstAte canceR 10355 Non-

Commercial RCHT Thomson, Dr Alastair 30-Jun-15 10 5 -78

ENZAMET 18429 Non-Commercial RCHT Thomson, Dr

Alastair 01-Oct-20 10 6 50

Hyperthermia for Intermediate risk bladder cancer (HIVEC-II) 15853 Non-

Commercial PHNTHunter Campbell, Mr Paul

08-Dec-17 10 8 51

IMPACT 4214 Non-Commercial PHNT Brewer, Dr

Carole 01-Apr-15 3 10 220

IMPACT 4214 Non-Commercial RD&E Brewer, Dr

Carole 31-Dec-16 20 36 97

Skin Tumour Group RAG Report - Non Commercial




Planned Target


Pazopanib in patients with renal cancer (PaZ02) 11827 Non-Commercial SDHCFT Lydon, Dr

Anna 31-Aug-16 2 2 39

POUT 11494 Non-Commercial NDHCT Sheehan, Dr

Denise 31-Jan-17 15 3 -53

POUT 11494 Non-Commercial RCHT Wheatley, Dr

Duncan 03-Jul-17 10 3 -31

POUT 11494 Non-Commercial RD&E Sheehan, Dr

Denise 30-May-17 9 2 -43

POUT 11494 Non-Commercial SDHCFT Lydon, Dr

Anna 30-May-17 3 2 8

POUT 11494 Non-Commercial T&S Varughese, Dr

Mohini 31-Dec-17 4 1 -32

PROMIS Prostate MRI Imaging Study (MRC PR11) 9941 Non-Commercial T&S Burns-Cox, Mr

Nick 31-Oct-15 45 35 -19

PROMPTS 13129 Non-Commercial NDHCT Sheehan, Dr

Denise 30-Jun-15 15 0 -111

PROMPTS 13129 Non-Commercial RD&E Sheehan, Dr

Denise 01-Dec-17 3 4 83

PROMPTS 13129 Non-Commercial T&S Graham, Dr

John 31-Dec-17 10 3 -20





Planned Target


RADICALS (MRC PR10) 1762 Non-Commercial NDHCT Sheehan, Dr

Denise 30-Jun-15 10 4 -64

RADICALS (MRC PR10) 1762 Non-Commercial PHNT Sells, Mr

Henry 01-May-20 10 21 149

RADICALS (MRC PR10) 1762 Non-Commercial RCHT Wheatley, Dr

Duncan 30-Jun-15 9 14 51

RADICALS (MRC PR10) 1762 Non-Commercial RD&E Srinivasan, Dr

Rajaguru 30-Jun-16 22 52 146

RADICALS (MRC PR10) 1762 Non-Commercial SDHCFT Lydon, Dr

Anna 30-Jun-16 20 18 -1

RADICALS (MRC PR10) 1762 Non-Commercial T&S Varughese, Dr

Mohini 30-Jun-15 45 34 -29

SAPROCAN: Saracatnib and docetaxel in met, cast-ref prostate cancer 11180 Non-

Commercial RD&E Srinivasan, Dr Rajaguru 15-Feb-16 6 4 -13

SAPROCAN: Saracatnib and docetaxel in met, cast-ref prostate cancer 11180 Non-

Commercial SDHCFT Lydon, Dr Anna 30-Apr-15 3 1 -102





Planned Target


Stampede 1409 Non-Commercial NDHCT Sheehan, Dr

Denise 31-Dec-17 8 27 267

Stampede 1409 Non-Commercial RD&E Sheehan, Dr

Denise 31-Dec-20 119 168 76

Stampede 1409 Non-Commercial SDHCFT Lydon, Dr

Anna 31-Dec-15 60 120 102

Stampede 1409 Non-Commercial T&S Graham, Dr

John 01-Jun-19 66 114 106

Stampede 1409 Non-Commercial YDH Sparrow, Dr

Geoff 31-Dec-20 12 5 14

STAR Standard vs Modified Drug Therapy in Renal Cancer 10674 Non-

Commercial RCHT Thomson, Dr Alastair 01-Nov-16 3 5 119


Commercial RD&E Sheehan, Dr Denise 31-May-17 5 5 67


Commercial T&S Varughese, Dr Mohini 31-May-17 6 0 -24


Commercial YDH Sparrow, Dr Geoff 03-Jun-16 2 1 -10



Acronym UKCRNID Study Type Trust Investigator Name Recruitment End Date

Planned Target


The Leeds Testicular Cancer Study 13737 Non-Commercial PHNT Highley, Dr Martin 31-Jan-18 30 18 42

The Leeds Testicular Cancer Study 13737 Non-Commercial RCHT Wheatley, Dr Duncan 30-Jan-18 40 70 139

The Leeds Testicular Cancer Study 13737 Non-Commercial RD&E Hong, Dr Anne 31-Jan-18 30 14 25

The PHOTO Trial 17055 Non-Commercial RD&E McGrath, Mr John 31-Mar-17 20 30 113

The UK Genetics of Testicular Cancer Study 4155 Non-Commercial PHNT Highley, Dr Martin 26-Sep-16 15 35 168

UK Genetic Prostate Cancer Study 869 Non-Commercial NDHCT Sheehan, Dr Denise 31-Dec-17 20 37 101

UK Genetic Prostate Cancer Study 869 Non-Commercial PHNT McInerney, Mr Paul 31-Dec-17 15 75 419

UK Genetic Prostate Cancer Study 869 Non-Commercial RCHT Wheatley, Dr Duncan 12-Dec-17 120 84 -10

UK Genetic Prostate Cancer Study 869 Non-Commercial RD&E Investigator, No Local 31-Dec-17 32 77 160

UK Genetic Prostate Cancer Study 869 Non-Commercial SDHCFT Lydon, Dr Anna 31-Dec-17 42 72 87

UK Genetic Prostate Cancer Study 869 Non-Commercial T&S MacDonagh, Dr Ru 31-Dec-17 12 86 636

UK Genetic Prostate Cancer Study 869 Non-Commercial YDH Parker, Mr Chris 31-Dec-17 5 36 669

VinCaP 15033 Non-Commercial RCHT Thomson, Dr Alastair 03-Feb-15 1 2 22



urological tumour group national perspective data from portfolio odp – cut off 23/10/15 includes...

Documents